A spinout of University of Maine, Neuright, Inc. is an ealy stage biotech firm addressing early diagnosis and treatment of peripheral neuropathy - a condition in which nerve fibers die back from the skin. Judged likely to affect some 20 million people in the US, symptoms including pain, numbness and loss of limb control. diabetes is understood to be a leading cause of the disease with some up 70% of diabetics like to have/develop the disease. However, with symptoms that can be quite different between patients, diagnosis can be difficult and, while there is no cure - early intervention and treatment can help those with a likelihood of developing the condition to minimize and manage the often debilitating effects. Anchored in work undertaken at University of Maine by the principals, in 2018 Neuright in 2018 was established to commercialize an affordable medical device structured to measure nerve conduction and to stimulate the regrowth of nerves. Building out from work undertaken at University of Maine, NeurightÂ’s technology evolved out research into brain-adipose communication and how peripheral nerves in adipose (fat) tissue function. The device being developed allows measurement of nerve electrical activity as an indication of neuropathic state, and is currently being tested in neuropathic mouse models.
